Amylyx Q2 net loss narrows to $41.4M; cash $180.8M; pipeline milestones on track

Amylyx Pharmaceuticals, Inc.

2025-Q2 EPS reported -$0.88

Net loss of $41.4M ($0.46 per share) vs $72.7M ($1.07) in Q2 2024; lower SG&A and R&D spend in ALS.
Cash, equivalents, and marketable securities $180.8M at June 30, 2025; runway expected through end of 2026.
Pivotal Phase 3 LUCIDITY trial of avexitide in PBH fully enrolled in 2025; topline data H1 2026; potential launch 2027.
Phase 2b ORION trial (AMX0035) in PSP unblinded analysis expected Q3 2025 to inform Phase 3 go/no-go.
FDA Fast Track granted for AMX0114 (antisense oligo) in ALS; early LUMINA Phase 1 data expected 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.